Q4 EPS Estimates for Guardant Health Increased by Analyst

Guardant Health, Inc. (NASDAQ:GH) – Investment analysts at Leerink Partnrs increased their Q4 2024 EPS estimates for shares of Guardant Health in a research report issued to clients and investors on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now anticipates that the company will post earnings per share of ($0.73) for the quarter, up from their previous estimate of ($0.76). The consensus estimate for Guardant Health’s current full-year earnings is ($3.44) per share. Leerink Partnrs also issued estimates for Guardant Health’s Q1 2025 earnings at ($0.62) EPS, Q2 2025 earnings at ($0.64) EPS, Q3 2025 earnings at ($0.60) EPS, Q4 2025 earnings at ($0.69) EPS, FY2025 earnings at ($2.54) EPS and FY2026 earnings at ($2.86) EPS.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.33). The firm had revenue of $191.48 million during the quarter, compared to the consensus estimate of $170.49 million. Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. Guardant Health’s revenue was up 33.9% on a year-over-year basis. During the same period last year, the business earned ($0.73) EPS.

Other research analysts have also recently issued reports about the stock. Guggenheim reissued a “buy” rating on shares of Guardant Health in a research report on Wednesday. The Goldman Sachs Group lifted their target price on shares of Guardant Health from $32.00 to $36.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Sanford C. Bernstein decreased their target price on shares of Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a report on Wednesday, October 30th. Leerink Partners decreased their target price on shares of Guardant Health from $60.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Guardant Health from $48.00 to $50.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Fifteen analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $40.60.

Guardant Health Stock Up 4.6 %

NASDAQ:GH opened at $47.20 on Thursday. The company has a 50-day moving average price of $34.53 and a 200-day moving average price of $29.26. Guardant Health has a 12 month low of $15.81 and a 12 month high of $49.86.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of GH. R Squared Ltd bought a new position in shares of Guardant Health in the fourth quarter worth about $26,000. KBC Group NV grew its holdings in shares of Guardant Health by 63.6% in the fourth quarter. KBC Group NV now owns 5,658 shares of the company’s stock worth $173,000 after purchasing an additional 2,200 shares during the last quarter. Wealthcare Advisory Partners LLC bought a new position in Guardant Health during the 4th quarter worth about $252,000. Fiduciary Alliance LLC lifted its position in shares of Guardant Health by 7.6% during the fourth quarter. Fiduciary Alliance LLC now owns 11,879 shares of the company’s stock valued at $363,000 after buying an additional 836 shares during the last quarter. Finally, Lord Abbett & CO. LLC purchased a new stake in shares of Guardant Health during the third quarter valued at about $15,624,000. Institutional investors own 92.60% of the company’s stock.

Insider Transactions at Guardant Health

In related news, Director Meghan V. Joyce sold 2,896 shares of the company’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $29.90, for a total transaction of $86,590.40. Following the sale, the director now owns 7,648 shares of the company’s stock, valued at $228,675.20. This represents a 27.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Musa Tariq sold 2,320 shares of the business’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $35.00, for a total transaction of $81,200.00. Following the transaction, the director now owns 2,676 shares in the company, valued at $93,660. This trade represents a 46.44 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 5,548 shares of company stock valued at $179,782. 5.50% of the stock is currently owned by corporate insiders.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.